Nifty
Sensex
:
:
11828.25
39352.67
421.10 (3.69%)
1421.90 (3.75%)

Pharmaceuticals & Drugs

Rating :
38/99

BSE: 532300 | NSE: WOCKPHARMA

387.70
22.85 (6.26%)
20-May-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  370.00
  •  391.90
  •  370.00
  •  364.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1241797
  •  4814.45
  •  749.00
  •  349.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,284.66
  • N/A
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,950.23
  • N/A
  • 1.51

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.07%
  • 2.20%
  • 14.24%
  • FII
  • DII
  • Others
  • 0.12%
  • 2.37%
  • 7.00%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -4.01
  • -4.02

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -71.80
  • -67.36

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -19.14
  • 101.92

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.82
  • 22.14
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.79
  • 2.98
  • 2.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 43.62
  • 66.60
  • 100.64

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
979.13
1,018.26
-3.84%
1,045.86
1,005.30
4.03%
1,125.68
1,022.28
10.11%
1,007.71
891.06
13.09%
Expenses
944.18
1,048.20
-9.92%
1,063.70
959.90
10.81%
1,073.59
1,013.83
5.89%
1,003.26
970.40
3.39%
EBITDA
34.95
-29.94
-
-17.84
45.40
-
52.09
8.45
516.45%
4.45
-79.34
-
EBIDTM
3.57%
-2.94%
-1.71%
4.52%
4.63%
0.83%
0.44%
-8.90%
Other Income
26.03
15.44
68.59%
2.08
38.35
-94.58%
21.42
67.41
-68.22%
7.43
56.29
-86.80%
Interest
63.54
64.97
-2.20%
63.60
61.81
2.90%
65.10
67.60
-3.70%
72.65
61.11
18.88%
Depreciation
45.44
38.21
18.92%
41.23
37.95
8.64%
40.20
36.19
11.08%
39.17
37.18
5.35%
PBT
-48.00
-117.68
-
-120.59
-16.01
-
-31.79
-27.93
-
-99.94
-479.53
-
Tax
-34.10
35.23
-
-43.73
26.54
-
-0.95
-19.11
-
-4.88
-16.96
-
PAT
-13.90
-152.91
-
-76.86
-42.55
-
-30.84
-8.82
-
-95.06
-462.57
-
PATM
-1.42%
-15.02%
-7.35%
-4.23%
-2.74%
-0.86%
-9.43%
-51.91%
EPS
-1.31
-13.97
-
-6.42
-3.69
-
-2.06
-0.30
-
-7.79
-37.05
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Dec 08
Net Sales
4,158.38
3,936.90
4,014.61
4,453.22
4,481.54
4,830.36
5,609.42
4,350.50
3,751.24
4,501.42
3,589.78
Net Sales Growth
5.63%
-1.94%
-9.85%
-0.63%
-7.22%
-13.89%
28.94%
15.97%
-16.67%
25.40%
 
Cost Of Goods Sold
1,814.63
1,797.53
1,662.07
1,613.68
1,487.48
1,806.25
1,747.56
1,534.38
1,516.22
1,972.54
1,360.35
Gross Profit
2,343.75
2,139.37
2,352.54
2,839.54
2,994.06
3,024.11
3,861.86
2,816.12
2,235.02
2,528.89
2,229.42
GP Margin
56.36%
54.34%
58.60%
63.76%
66.81%
62.61%
68.85%
64.73%
59.58%
56.18%
62.10%
Total Expenditure
4,084.73
3,935.07
3,988.39
3,958.98
3,772.14
3,804.65
3,549.74
2,996.79
2,835.28
3,731.04
2,933.74
Power & Fuel Cost
-
77.80
110.10
113.99
101.40
92.17
97.08
80.38
55.83
58.36
56.99
% Of Sales
-
1.98%
2.74%
2.56%
2.26%
1.91%
1.73%
1.85%
1.49%
1.30%
1.59%
Employee Cost
-
937.06
966.51
950.77
868.87
768.63
655.90
572.91
542.41
730.30
629.10
% Of Sales
-
23.80%
24.07%
21.35%
19.39%
15.91%
11.69%
13.17%
14.46%
16.22%
17.52%
Manufacturing Exp.
-
135.27
179.40
228.07
236.03
240.85
180.06
115.03
110.79
135.10
137.51
% Of Sales
-
3.44%
4.47%
5.12%
5.27%
4.99%
3.21%
2.64%
2.95%
3.00%
3.83%
General & Admin Exp.
-
475.24
504.43
405.85
320.92
352.19
248.28
194.47
198.73
234.13
179.13
% Of Sales
-
12.07%
12.56%
9.11%
7.16%
7.29%
4.43%
4.47%
5.30%
5.20%
4.99%
Selling & Distn. Exp.
-
208.89
205.30
241.11
261.55
292.98
291.74
214.75
186.16
219.81
218.33
% Of Sales
-
5.31%
5.11%
5.41%
5.84%
6.07%
5.20%
4.94%
4.96%
4.88%
6.08%
Miscellaneous Exp.
-
303.28
360.58
405.51
495.89
251.58
329.12
284.87
225.14
380.80
218.33
% Of Sales
-
7.70%
8.98%
9.11%
11.07%
5.21%
5.87%
6.55%
6.00%
8.46%
9.81%
EBITDA
73.65
1.83
26.22
494.24
709.40
1,025.71
2,059.68
1,353.71
915.96
770.38
656.04
EBITDA Margin
1.77%
0.05%
0.65%
11.10%
15.83%
21.23%
36.72%
31.12%
24.42%
17.11%
18.28%
Other Income
56.96
120.23
100.83
66.10
66.55
38.40
54.00
25.34
152.62
29.52
46.11
Interest
264.89
255.49
225.27
128.96
55.21
83.35
215.37
269.02
267.10
342.48
259.07
Depreciation
166.04
149.53
148.93
141.91
145.40
139.92
122.14
115.07
116.62
148.14
113.05
PBT
-300.32
-282.96
-247.15
289.47
575.34
840.84
1,776.17
994.96
684.86
309.29
330.03
Tax
-83.66
25.70
-21.11
37.88
162.65
47.88
258.21
221.74
8.65
16.67
-91.62
Tax Rate
27.86%
-4.01%
8.54%
13.09%
28.27%
5.38%
14.05%
42.54%
8.29%
-1.69%
36.51%
PAT
-216.66
-608.30
-195.72
250.08
404.91
840.72
1,579.48
299.45
95.70
-1,002.30
-159.34
PAT before Minority Interest
-194.53
-666.85
-226.04
251.59
412.69
842.79
1,579.48
299.45
95.70
-1,002.30
-159.34
Minority Interest
22.13
58.55
30.32
-1.51
-7.78
-2.07
0.00
0.00
0.00
0.00
0.00
PAT Margin
-5.21%
-15.45%
-4.88%
5.62%
9.04%
17.40%
28.16%
6.88%
2.55%
-22.27%
-4.44%
PAT Growth
0.00%
-
-
-38.24%
-51.84%
-46.77%
427.46%
212.90%
-
-
 
Unadjusted EPS
-17.58
-55.01
-17.71
22.71
36.81
76.64
145.61
31.31
8.27
-91.44
-12.69

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Dec 08
Shareholder's Funds
2,852.15
3,336.71
3,775.12
3,715.35
3,581.47
2,704.18
1,471.02
943.10
671.75
1,017.73
Share Capital
55.32
55.27
55.25
353.59
353.43
353.34
816.09
799.93
723.30
54.72
Total Reserves
2,760.11
3,244.43
3,691.22
3,315.65
3,182.73
2,319.30
644.73
143.17
-51.55
963.01
Non-Current Liabilities
2,088.89
3,151.38
1,893.49
1,872.46
1,161.18
1,520.80
2,891.88
2,943.95
3,969.89
4,193.61
Secured Loans
2,167.84
2,887.11
1,647.34
1,180.25
1,096.27
1,467.51
2,697.34
2,785.34
3,552.21
3,160.86
Unsecured Loans
5.27
303.16
273.26
4.59
6.03
7.64
9.05
9.15
465.32
1,074.26
Long Term Provisions
64.89
94.23
70.74
635.05
51.98
69.85
84.49
224.31
0.00
0.00
Current Liabilities
2,691.71
1,978.81
1,841.85
1,772.97
1,743.20
1,773.48
1,890.94
1,919.01
1,031.27
1,630.28
Trade Payables
601.78
533.81
637.69
552.56
557.79
634.15
540.80
436.58
435.44
523.45
Other Current Liabilities
1,548.13
690.13
621.23
844.44
947.70
789.96
978.38
1,068.86
363.77
332.96
Short Term Borrowings
437.09
662.80
550.03
348.28
210.20
182.00
260.80
390.06
0.00
0.00
Short Term Provisions
104.71
92.07
32.90
27.69
27.51
167.37
110.96
23.51
232.05
773.87
Total Liabilities
7,978.48
8,848.84
7,975.79
7,504.73
6,622.02
5,998.46
6,253.84
5,806.06
5,672.91
6,841.62
Net Block
2,887.96
2,772.55
2,808.70
2,122.74
2,294.63
1,989.60
2,571.34
2,580.22
2,529.43
2,996.17
Gross Block
5,772.29
5,456.40
4,377.01
4,552.96
4,642.81
4,295.75
4,211.60
4,048.65
3,834.34
3,989.56
Accumulated Depreciation
2,884.33
2,683.85
1,568.31
2,430.22
2,348.18
1,684.94
1,306.76
1,439.10
1,038.73
988.17
Non Current Assets
4,598.88
4,313.57
4,023.94
3,983.17
3,266.10
2,671.53
3,772.33
3,903.85
3,331.83
3,722.87
Capital Work in Progress
1,432.57
1,243.95
1,036.05
1,007.30
707.53
490.94
902.29
862.70
707.57
633.50
Non Current Investment
0.45
0.45
0.45
2.62
2.62
2.63
90.75
89.63
94.83
93.19
Long Term Loans & Adv.
277.90
296.62
178.74
845.68
235.86
183.35
207.95
371.30
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
4.83
25.46
5.01
0.00
0.00
0.00
0.00
Current Assets
3,379.60
4,535.27
3,951.85
3,521.56
3,355.92
3,326.93
2,481.51
1,902.21
2,341.07
3,118.74
Current Investments
213.25
562.27
0.00
338.72
573.98
0.00
0.00
0.00
0.00
0.00
Inventories
855.71
1,107.95
1,102.16
1,020.78
992.89
1,058.83
888.56
713.73
765.45
829.75
Sundry Debtors
962.45
1,034.45
1,111.42
741.43
481.04
958.46
758.69
605.24
574.01
853.42
Cash & Bank
1,082.25
1,603.61
1,478.11
1,234.55
1,125.80
1,096.06
699.99
482.89
346.98
649.91
Other Current Assets
265.94
29.24
0.00
0.00
182.21
213.58
134.27
100.35
654.63
785.65
Short Term Loans & Adv.
257.63
197.75
260.16
186.08
182.21
213.58
134.27
100.35
654.63
785.65
Net Current Assets
687.89
2,556.46
2,110.00
1,748.59
1,612.72
1,553.45
590.57
-16.80
1,309.80
1,488.46
Total Assets
7,978.48
8,848.84
7,975.79
7,504.73
6,622.02
5,998.46
6,253.84
5,806.06
5,672.90
6,841.61

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Dec 08
Cash From Operating Activity
68.44
-269.47
71.61
354.96
1,476.29
1,532.40
1,343.83
641.81
-198.68
124.50
PBT
-641.15
-247.15
357.01
575.34
890.67
1,860.20
576.72
104.35
-985.64
-250.96
Adjustment
448.78
303.04
201.29
285.63
133.53
273.31
917.59
495.44
1,078.01
976.29
Changes in Working Capital
278.33
-297.39
-402.76
-344.62
587.99
-266.99
-129.94
44.99
-244.20
-569.67
Cash after chg. in Working capital
85.96
-241.50
155.54
516.35
1,612.19
1,866.52
1,364.37
644.78
-151.82
155.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-17.52
-27.97
-83.93
-161.39
-135.90
-334.12
-20.54
-2.97
-46.85
-31.15
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
630.24
-686.64
-818.19
-206.63
-851.62
1,085.37
-305.45
-276.61
704.33
-1,198.09
Net Fixed Assets
-45.55
-166.75
-368.17
-299.87
-283.99
174.15
-181.64
-415.22
-136.60
-330.13
Net Investments
0.00
0.00
0.00
10.73
0.00
0.00
0.00
7.69
-13.04
-0.13
Others
675.79
-519.89
-450.02
82.51
-567.63
911.22
-123.81
130.92
853.97
-867.83
Cash from Financing Activity
-769.47
1,254.49
254.26
-75.65
-601.32
-2,245.75
-826.56
-372.99
-395.67
1,039.87
Net Cash Inflow / Outflow
-70.79
298.38
-492.32
72.68
23.35
372.02
211.82
-7.79
109.98
-33.72
Opening Cash & Equivalents
963.64
662.98
1,158.69
1,101.65
1,050.01
689.66
470.10
314.10
212.16
377.25
Closing Cash & Equivalent
897.24
963.64
664.64
1,158.69
1,101.65
1,050.01
689.66
470.10
314.10
212.16

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Dec 08
Book Value (Rs.)
254.47
298.51
339.05
306.20
294.97
216.65
63.91
18.08
0.29
93.00
ROA
-7.93%
-2.69%
3.25%
6.09%
13.36%
25.78%
4.97%
1.67%
-16.02%
-2.65%
ROE
-21.81%
-6.42%
7.07%
12.49%
30.04%
102.78%
66.74%
95.20%
-196.36%
-13.91%
ROCE
-5.47%
-0.31%
6.87%
11.25%
18.98%
43.10%
17.39%
8.23%
-12.94%
0.17%
Fixed Asset Turnover
0.70
0.82
1.00
0.98
1.08
1.32
1.05
0.95
1.15
0.97
Receivable days
92.57
97.55
75.93
49.71
54.33
55.81
57.17
57.31
57.81
77.27
Inventory Days
91.03
100.47
87.00
81.88
77.43
63.29
67.16
71.89
64.61
81.23
Payable days
65.61
64.08
64.54
63.71
65.00
65.49
65.74
63.23
53.78
69.42
Cash Conversion Cycle
117.98
133.94
98.39
67.88
66.75
53.61
58.58
65.97
68.64
89.08
Total Debt/Equity
1.33
1.26
0.71
0.55
0.54
0.77
2.25
3.60
5.98
4.16
Interest Cover
-1.51
-0.10
3.24
11.42
11.69
9.53
2.94
1.39
-1.88
0.03

News Update:


  • UK MHRA’s approval status on Wockhardt’s Daman facilities continues
    13th May 2019, 14:35 PM

    EudraGMDP is the name of the European Union database which inter-alia contains Good Manufacturing Practice certificates

    Read More
  • Wockhardt’s Q4 consolidated net loss narrows to Rs 14 crore
    7th May 2019, 11:13 AM

    The company has reported a standalone net loss of Rs 33.52 crore for the quarter ended March 31, 2019

    Read More
  • Wockhardt - Quarterly Results
    6th May 2019, 16:38 PM

    Read More
  • Wockhardt planning to raise funds via various sources
    22nd Apr 2019, 14:26 PM

    The meeting of the Board of Directors of the Bank is scheduled to be held on May 06, 2019, to consider the same

    Read More
  • USFDA completes inspection of Wockhardt’s Bioequivalence Centre
    15th Apr 2019, 09:51 AM

    At the end of inspection, there was nil observation, signifying that best practices were followed, in compliance to applicable regulations

    Read More
  • Wockhardt gets USFDA’s nod for injection of Decitabine
    11th Apr 2019, 09:01 AM

    According to IQVIA February 2019 data, the product has sales of $120 million in the US

    Read More
  • HPRA grants GMP Certificate to Wockhardt’s Aurangabad facility
    27th Mar 2019, 10:24 AM

    Health Products Regulatory Authority, Ireland and UK MHRA have carried out joint Inspection of Shendra, Aurangabad facility

    Read More
  • Wockhardt incorporates subsidiary company
    27th Mar 2019, 09:59 AM

    The WML is incorporated with an Authorised Share Capital of Rs 10 lakh

    Read More
  • Wockhardt gets USFDA’s approval for Prostate cancer drug
    1st Mar 2019, 15:23 PM

    Wockhardt's Abiraterone acetate tablet is a generic version of Zytiga, marketed in USA and other countries by Johnson & Johnson

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.